Key facts
- Flyte (Therapeutic Devices)’s last known valuation is $11.5M (Sep 2024).
- It has raised $6.6M; the latest was Later Stage VC ($140K) in Apr 2025.
- Notable investors include Matter (Consulting Services (B2B)), Boomerang Ventures, Life Science Angels, Pier 70 Ventures, TCA Venture Group — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Flyte (Therapeutic Devices)
- ·The full record, as it builds
Funding rounds
No funding rounds for Flyte (Therapeutic Devices) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Flyte (Therapeutic Devices)
Developer of a medical device designed to treat mild, moderate, and severe female stress urinary incontinence. The company's device uses technology capable of delivering mechanotherapy, which is a proven method for healing and strengthening muscle systems, enabling patients who suffer from pelvic floor disorders to significantly improve their lives.
- Sector
- Healthcare
- HQ
- Eagan, MN, United States
- Founded
- 2016
- Employees
- 10
- Website
- flytesystem.com/
- Ownership
- Privately Held (backing)
Flyte (Therapeutic Devices) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Flyte (Therapeutic Devices) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Flyte (Therapeutic Devices) in its N-PORT filings yet. We sweep new filings monthly.